Alphatec beats Q2 revenue estimates, raises FY guidance

Alphatec Holdings

31/07/2025 21:22

Overview

Alphatec Q2 revenue grows 27.5%, beating analysts' expectations, per LSEG data

Adjusted EBITDA for Q2 beats consensus, reflecting disciplined execution

Company raises full-year revenue and profitability guidance

Outlook

Company expects full-year 2025 revenue to grow 21% to $742 mln

Alphatec raises full-year 2025 adjusted EBITDA guidance to $83 mln

Company projects 2025 surgical revenue of $666 mln

Alphatec anticipates EOS revenue of $76 mln in 2025

Result Drivers

SURGICAL REVENUE - 29% growth driven by momentum of PTP™ and LTP™ solutions

SURGEON ADOPTION - 21% increase in new surgeon adoption, indicating future growth potential

EBITDA MARGIN EXPANSION - Adjusted EBITDA margin expanded by 880 bps YoY through disciplined execution

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$186 mln
$178.80 mln (9 Analysts)
Q2 Net Income
-$41 mln
Q2 Adjusted EBITDA
Beat
$23 mln
$17.80 mln (8 Analysts)
Q2 Gross Margin
70.0%
Q2 Adjusted Gross Margin
70.0%
Q2 Basic EPS
-$0.27
Q2 Operating Income
-$13.08 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Alphatec Holdings Inc is $20.00, about 46.3% above its July 30 closing price of $10.73

Press Release: ID:nBw5Vj6HRa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)